The Centers for Disease Control and Prevention (CDC) intends to award a sole source contract to Beacon Scientific INC for the manufacture of 10,000 lateral flow devices to detect HIV antiretroviral usage in point-of-care settings. The work is for pre-clinical and clinical studies, and the government considers Beacon Scientific the only capable source due to its proprietary nanoparticle materials. Responses to this notice of intent must be submitted by email to the contract specialist by June 2, 2026. No budget amount is specified in the description. The location for performance of services is not mentioned.